252 related articles for article (PubMed ID: 22851637)
41. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.
Cescato R; Erchegyi J; Waser B; Piccand V; Maecke HR; Rivier JE; Reubi JC
J Med Chem; 2008 Jul; 51(13):4030-7. PubMed ID: 18543899
[TBL] [Abstract][Full Text] [Related]
42. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
[TBL] [Abstract][Full Text] [Related]
43. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
Antunes P; Ginj M; Zhang H; Waser B; Baum RP; Reubi JC; Maecke H
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):982-93. PubMed ID: 17225119
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.
Wang X; Fani M; Schulz S; Rivier J; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1876-85. PubMed ID: 22926735
[TBL] [Abstract][Full Text] [Related]
45. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of receptors for somatostatin in various tumors using different analogs.
Srkalovic G; Cai RZ; Schally AV
J Clin Endocrinol Metab; 1990 Mar; 70(3):661-9. PubMed ID: 1968467
[TBL] [Abstract][Full Text] [Related]
47. Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist.
Rajeswaran WG; Hocart SJ; Murphy WA; Taylor JE; Coy DH
J Med Chem; 2001 Apr; 44(8):1305-11. PubMed ID: 11312929
[TBL] [Abstract][Full Text] [Related]
48. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
49. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
50. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [
Tatsi A; Maina T; Waser B; Krenning EP; de Jong M; Reubi JC; Cordopatis P; Nock BA
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339198
[TBL] [Abstract][Full Text] [Related]
51. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
52. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
53. Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
Rivier J; Erchegyi J; Hoeger C; Miller C; Low W; Wenger S; Waser B; Schaer JC; Reubi JC
J Med Chem; 2003 Dec; 46(26):5579-86. PubMed ID: 14667212
[TBL] [Abstract][Full Text] [Related]
54. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1).
Rivier JE; Hoeger C; Erchegyi J; Gulyas J; DeBoard R; Craig AG; Koerber SC; Wenger S; Waser B; Schaer JC; Reubi JC
J Med Chem; 2001 Jun; 44(13):2238-46. PubMed ID: 11405660
[TBL] [Abstract][Full Text] [Related]
55. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y.
Maurin M; Garnuszek P; Baran P; Pawlak D; Mikołajczak R
Nucl Med Rev Cent East Eur; 2015; 18(2):51-5. PubMed ID: 26315862
[TBL] [Abstract][Full Text] [Related]
56. Preclinical study of a new
Behnammanesh H; Erfani M; Hajiramezanali M; Jokar S; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Beiki D
Asia Ocean J Nucl Med Biol; 2020; 8(2):109-115. PubMed ID: 32714998
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
